EGFR and colorectal carcinoma: PHA-665752 and cabozantinib demonstrated potent growth inhibition in METex14+ GC and CRC PDCs whereas lapatinib, an EGFR and HER2 inhibitor, and cetuximab (Erbitux), an EGFR targeting monoclonal antibody exhibited no such effects (Supplementary Figure S3C).